Treatment of myelodysplastic syndrome

Abstract

The present invention relates to the use of Volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (MDS).

1 . A method of treating MDS comprising administering to a patient a therapeutically effective amount of Volasertib, optionally in the form of a pharmaceutically acceptable salt thereof or a hydrate thereof. 
     
     
         2 . The method according to  claim 1  wherein the treatment is a 2 nd  line treatment after one prior therapy or the treatment is a 3 rd  line treatment after two different prior therapies. 
     
     
         3 . The method according to  claim 1  wherein higher-risk MDS is treated. 
     
     
         4 . The method according to  claim 1 , wherein 150 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof are administered per day of administration. 
     
     
         5 . The method according to  claim 4  wherein Volasertib is administered on one day during a 4 week treatment cycle. 
     
     
         6 . The method according to  claim 4  wherein Volasertib is administered on two days during a 4 week treatment cycle. 
     
     
         7 . The method according to  claim 4  wherein Volasertib is administered on three days during a 4 week treatment cycle. 
     
     
         8 . The method according to  claim 4  wherein Volasertib is administered on one day during a 3 week treatment cycle. 
     
     
         9 . The method according to  claim 4  wherein Volasertib is administered on two days during a 3 week treatment cycle. 
     
     
         10 . The method according to  claim 4  wherein Volasertib is administered on three days during a 3 week treatment cycle. 
     
     
         11 . A pharmaceutical kit comprising a therapeutically effective amount of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof for use of treating MDS.